Dapagliflozin [Farxiga^® (USA); Forxiga^® (EU)], a sodium–glucose cotransporter 2 (SGLT2) inhibitor, was recently approved in the USA and the EU for the treatment of adults with symptomatic heart failure with reduced ejection fraction (HFrEF). The cardiovascular (CV) benefits of dapagliflozin were first observed in the DECLARE-TIMI 58 trial, in which dapagliflozin 10 mg/day significantly reduced the risk of CV death or hospitalization for HF in patients with type 2 diabetes mellitus (T2DM) who had or were at risk for atherosclerotic CV disease. In the subsequent DAPA-HF trial, dapagliflozin 10 mg/day in addition to standard of care was associated with a significantly lower risk of worsening HF or CV death than placebo in patients with HFrEF, regardless of the presence or absence of T2DM. The benefits of dapagliflozin also remained consistent regardless of background HF therapies. Dapagliflozin was generally well tolerated, with an overall safety profile consistent with its known safety profile in other indications. In conclusion, dapagliflozin is an effective and generally well-tolerated treatment that represents a valuable new addition to the options available for symptomatic HFrEF.

达格列净 [Farxiga ^® （美国）； Forxiga ^® (EU)] 是一种钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂，最近在美国和欧盟获得批准，用于治疗射血分数降低 (HFrEF) 的症状性心力衰竭成人患者。达格列净对心血管 (CV) 的益处首次在 DECLARE-TIMI 58 试验中观察到，其中达格列净 10 mg/天可显着降低患有或患有 2 型糖尿病 (T2DM) 的 2 型糖尿病 (T2DM) 患者的 CV 死亡或因心力衰竭住院的风险。有患动脉粥样硬化性心血管疾病的风险。在随后的 DAPA-HF 试验中，对于 HFrEF 患者，无论是否存在 T2DM，在标准护理的基础上加用达格列净 10 mg/天，与安慰剂相比，HF 或 CV 死亡恶化的风险显着降低。无论背景心力衰竭治疗如何，达格列净的益处也保持一致。达格列净总体耐受性良好，总体安全性与其已知的其他适应症安全性一致。总之，达格列净是一种有效且普遍耐受性良好的治疗方法，为症状性 HFrEF 的选择提供了有价值的新补充。